Liang 2019.

Study characteristics
Methods	Design: CRT Follow‐up: 12 months Control group: usual care
Participants	Recruitment: general practice Assessed for eligibility: 1050 Randomly assigned: SM: 157; UC: 115 Completed: SM: 138; UC: 100 Mean age: SM: 66.6 (SD 10.8) years; UC: 61.7 (SD 10.1) years Gender (% male): SM: 60.5; UC: 62.6 COPD diagnosis: GOLD criteria, confirmed with spirometry (FEV1/FVC ratio < 0.7) Inclusion of participants in acute phase: no Major inclusion criteria: ≥ 40 years old, ≥ 2 clinic visits during the previous year, self‐reported being a current/ex‐smoker (≥ 10 pack‐year smoking history), documented diagnosis of COPD on clinic records or were being treated with COPD‐specific medications Major exclusion criteria: terminal illness (anticipated survival < 12 months), unable to provide informed consent (e.g. cognitive impairment), pre‐existing interstitial lung disease, unstable cardiovascular status, comorbidities preventing participation in an exercise training programme, contraindications to spirometry, completed pulmonary rehabilitation in the previous 24 months
Interventions	Mode: individual sessions at the general practice; phone calls Duration: 3 face‐to‐face individual sessions (duration not specified), and 9 phone calls (duration not specified) Professional: physiotherapist, research assistants, pharmacist Assignment of case managers: no Self‐management components: smoking cessation (optional), home based exercise, COPD medication intake (i.e. adherence, inhalation technique) Self‐management topics: not reported Behavioural change techniques: 5 clusters: goals and planning, feedback and monitoring, social support, natural consequences, reward and threat
Outcomes	1. HRQoL (SGRQ) 2. CAT 3. Dyspnoea (mMRC) 4. Lung function (FEV1 % predicted) 5. Anxiety and depression (HADS) 6. HSI 7. Smoking abstinence
Notes	Source of funding: this study was supported by Boehringer Ingelheim, Eastern Melbourne Primary Health Network, Lung Foundation Australia and National Health and Medical Research Council. Conflict of interest: MJ Abramson reports grants from Boehringer Ingelheim, during the conduct of the study; grants from Pfizer, assistance with conference attendance and personal fees for consultancy from Sanofi, outside the submitted work. G Russell has nothing to disclose. AE Holland is a current member of the Lung Foundation Australia COPD‐X: Concise Guide for Primary Care Advisory Committee. NA Zwar is a current member of the Lung Foundation Australia COPD Guidelines Committee. B Bonevski has nothing to disclose. A Mahal has nothing to disclose. P Eustace has nothing to disclose. E Paul has nothing to disclose. K Phillips is the Lung Foundation Australia General Manager of Consumer Programs. The Lung Foundation Australia works in collaboration and receives funding from pharmaceutical companies outlined in the foundation’s annual reports (available at lungfoundation.com.au/about‐us/annual‐reports/). NS Cox has nothing to disclose. S Wilson has nothing to disclose. J George reports grants from Boehringer Ingelheim, during the conduct of the study; grants from Pfizer, and personal fees for consultancy from GlaxoSmithKline, outside the submitted work; and is a current member of the Lung Foundation Australia COPD Guidelines Committee. J Liang has nothing to disclose.